Publikationer från Malmö universitet
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Three-Dimensional Oral Mucosal Equivalents as Models for Transmucosal Drug Permeation Studies
Malmö universitet, Fakulteten för hälsa och samhälle (HS), Institutionen för biomedicinsk vetenskap (BMV). Malmö universitet, Biofilms Research Center for Biointerfaces.
Malmö universitet, Fakulteten för hälsa och samhälle (HS), Institutionen för biomedicinsk vetenskap (BMV). Malmö universitet, Biofilms Research Center for Biointerfaces.
Malmö universitet, Odontologiska fakulteten (OD).
Malmö universitet, Fakulteten för hälsa och samhälle (HS), Institutionen för biomedicinsk vetenskap (BMV). Malmö universitet, Biofilms Research Center for Biointerfaces.ORCID-id: 0000-0003-1383-754X
Vise andre og tillknytning
2023 (engelsk)Inngår i: Pharmaceutics, ISSN 1999-4923, E-ISSN 1999-4923, Vol. 15, nr 5, s. 1513-1513Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Oral transmucosal administration, where drugs are absorbed directly through the non-keratinized, lining mucosa of the mouth, represents a solution to drug delivery with several advantages. Oral mucosal equivalents (OME) developed as 3D in vitro models are of great interest since they express the correct cell differentiation and tissue architecture, simulating the in vivo conditions better than monolayer cultures or animal tissues. The aim of this work was to develop OME to be used as a membrane for drug permeation studies. We developed both full-thickness (i.e., connective plus epithelial tissue) and split-thickness (i.e., only epithelial tissue) OME using non-tumor-derived human keratinocytes OKF6 TERT-2 obtained from the floor of the mouth. All the OME developed here presented similar transepithelial electrical resistance (TEER) values, comparable to the commercial EpiOral™. Using eletriptan hydrobromide as a model drug, we found that the full-thickness OME had similar drug flux to EpiOral™ (28.8 vs. 29.6 µg/cm2/h), suggesting that the model had the same permeation barrier properties. Furthermore, full-thickness OME showed an increase in ceramide content together with a decrease in phospholipids in comparison to the monolayer culture, indicating that lipid differentiation occurred due to the tissue-engineering protocols. The split-thickness mucosal model resulted in 4–5 cell layers with basal cells still undergoing mitosis. The optimum period at the air–liquid interface for this model was twenty-one days; after longer times, signs of apoptosis appeared. Following the 3R principles, we found that the addition of Ca2+, retinoic acid, linoleic acid, epidermal growth factor and bovine pituitary extract was important but not sufficient to fully replace the fetal bovine serum. Finally, the OME models presented here offer a longer shelf-life than the pre-existing models, which paves the way for the further investigation of broader pharmaceutical applications (i.e., long-term drug exposure, effect on the keratinocytes’ differentiation and inflammatory conditions, etc.).

sted, utgiver, år, opplag, sider
MDPI, 2023. Vol. 15, nr 5, s. 1513-1513
Emneord [en]
oral transmucosal delivery, oral mucosal equivalents, drug permeation, 3R principles, 3D in vitro models
HSV kategori
Identifikatorer
URN: urn:nbn:se:mau:diva-61046DOI: 10.3390/pharmaceutics15051513ISI: 000997495400001PubMedID: 37242755Scopus ID: 2-s2.0-85160448981OAI: oai:DiVA.org:mau-61046DiVA, id: diva2:1770819
Forskningsfinansiär
The Crafoord Foundation, 20210937Knowledge Foundation, 20190010Tilgjengelig fra: 2023-06-19 Laget: 2023-06-19 Sist oppdatert: 2023-08-15bibliografisk kontrollert

Open Access i DiVA

fulltext(3422 kB)193 nedlastinger
Filinformasjon
Fil FULLTEXT01.pdfFilstørrelse 3422 kBChecksum SHA-512
79c0e9bfbb17db2c325ea723743884f656482e32bc91f9b46d5647c234bf11b9789998fa8d383bbf50e9649330c724be156303ac346bafb68b978aa8c978d231
Type fulltextMimetype application/pdf

Andre lenker

Forlagets fulltekstPubMedScopus

Person

Riaz, AzraGidvall, SannaPrgomet, ZdenkaRuzgas, TautgirdasNilsson, Emelie J.Davies, Julia RValetti, Sabrina

Søk i DiVA

Av forfatter/redaktør
Riaz, AzraGidvall, SannaPrgomet, ZdenkaHernandez, Aura RocioRuzgas, TautgirdasNilsson, Emelie J.Davies, Julia RValetti, Sabrina
Av organisasjonen
I samme tidsskrift
Pharmaceutics

Søk utenfor DiVA

GoogleGoogle Scholar
Totalt: 193 nedlastinger
Antall nedlastinger er summen av alle nedlastinger av alle fulltekster. Det kan for eksempel være tidligere versjoner som er ikke lenger tilgjengelige

doi
pubmed
urn-nbn

Altmetric

doi
pubmed
urn-nbn
Totalt: 184 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf